Protease-Antiprotease Imbalance in Inflammatory Diseases in the Lung

To the Editor:
We are very interested in the extensive research by Vernooy et al, 1 who addressed the importance of matrix metalloproteases (MMPs) in the pathogenesis and/or the development of COPD. It is likely to be important to evaluate the activity of the proteases rather than the expression of MMPs. Protease/antiprotease imbalance has also been postulated to be important in the pathogenesis of COPD. However, the authors did not refer to the activity of the inhibitor of MMPs, tissue inhibitor of metalloprotease (TIMP). Thus, evaluation of the activity of TIMP will increase the understanding of the disease.
We are focusing on another protease inhibitor in several inflammatory conditions. Urinary trypsin inhibitor (UTI) is a multivalent Kunitz-type serine protease inhibitor. 2 UTI has been widely used as a drug for patients with disseminated intravascular coagulation, shock, and pancreatitis, especially in Japan. UTI can inhibit proteases including trypsin, ␣-chymotrypsin, plasmin, cathepsin G, and leukocyte elastase as well as proteases in the coagulation cascade. Also, UTI has been reported to have anti-inflammatory properties in vitro. For instances, UTI inhibits the enhanced production of proinflammatory molecules such as thromboxane B 2 , 3 interleukin-8, 4 and tumor necrosis factor-␣ 5 induced by lipopolysaccharide in vitro. In addition, UTI ameliorates several inflammatory models including ischemia-reperfusion injury, 6 hemorrhagic shock, 7 septic shock, 8 and glomerulonephritis 9 in vivo. We have recently exhibited the protective role of UTI in systemic inflammatory model using UTI gene knockout mice. 10 The protection was characterized by the inhibition of organ (lung, kidney, and liver) injuries and the enhanced organ expression of proinflammatory cytokines and chemokines. 10 More recently, we have demonstrated the protective role of UTI in acute lung injury induced by intratracheal administration of bacterial endotoxin in vivo, 11 and have shown that the protection is associated with the inhibition of enhanced lung expression of intercellular adhesion molecule- 1. 11 Indeed, the amount of UTI in serum reportedly reflects the degree of airway inflammation in children with asthma. 12 In conclusion, further investigation targeting protease inhibitors including UTI in inflammatory pulmonary diseases such as COPD may provide novel therapeutic strategies for the diseases. 
Ken-ichiro
To the Editor:
We appreciate the interest of Dr. Inoue and his group in our work. We fully endorse the importance of studying the protease/ antiprotease balance rather than the expression of proteases. We therefore applied specific immunocapture activity assays that measure any active matrix metalloproteinase (MMP) but are insensitive to MMP-inhibitor complexes (such as MMP-tissue inhibitor of metalloproteinase or MMP-␣2M complexes). Our finding of active MMPs in sputum is therefore indicative of a protease-antiprotease imbalance in COPD patients. The possible involvement of urinary trypsin inhibitor (UTI) is interesting, and the role of UTIs in COPD merits further study. Yet UTI (a serine protease inhibitor) does not inhibit MMP activity and will thus not influence the MMP-anti protease balance.
J.H.J. Vernooy, PhD University Hospital Maastricht
Maastricht, the Netherlands 
Patterns of Melanoma Antigen-A Expression in Lung Cancer Patients
To the Editor: , that each patient has a position in both lists, and that markers to the left of the patient in either list have negative results. This pair of lists generates all except one of the observed patterns, the exception being that one patient has negative results for C and D.
It is chance that the lists are the reverse of each other. As a concise description of the data, Table 1 (part c) is not unique. The positioning of E is ambiguous, as it could be first in the first list and last in the second list.
An alternative analysis might start from part (a) of Table 1 and employ a "positive-implies-positive" rule. This is not successful for this data set, as so many of the markers occur as the only positive result, in one patient or another.
If the lists in part (c) of Table 1 are taken seriously, they might be considered a theory and interpreted as resiliencies of the different MAGE markers, with a patient's positions reflecting the strengths of the two systems for suppressing them. I have used the same method of summarizing data in the context of which patients do or do not succeed at various neuropsychological tests, 2 and which chemicals do or do not kill various microorganisms. 3 Interpretations could be made in terms of systems damaged to lesser or greater degrees, with a rule either saying both components are needed or saying one component is sufficient for a certain outcome. The method has disadvantages, admittedly. It is silent about degrees of response, dealing only with a 0/1 dichotomy, and there is no random element.
Reservations About the Data
Treating Tables 1 and 2 of the study by Mecklenburg et al 1 as a single data set is questionable. They refer to induced sputum and BAL fluid, respectively. Moreover, the level of MAGE expression is reported as being much higher in Table 2 . It is arguable that marker C should have been excluded from consideration, since it is a conflation of MAGE-3 and MAGE-6 (see page 253 of the article by Kufer et al 4 ). Repeated observations from the same patient are not available, so allowance cannot be made for possible errors.
I hope that part (c) of Table 1 is thought-provoking despite the preceding paragraph, and that the proposed method of summarizing patterns of expression may be useful with other data sets. To the Editor:
We thank Dr. Hutchinson for his detailed statistical review of our described melanoma antigen (MAGE) expression profiles in sputum and bronchial fluid of lung cancer patients. 1 We definitely agree to his notion that different MAGE expression patterns need further attention, as the distinct expression of individual markers might have particular prognostic impact or may be used for further subclassification of disease.
However, comprehensive analysis of large cohorts of patients with different types of cancers have not yielded any transparent order of distribution yet. Moreover, the additional quantitative assessment of MAGE expression by real-time polymerase chain reaction displays a rather arbitrary gene activity of individual markers in different types of tumors (unpublished data), and the sensitivity threshold of the utilized assay markedly affects the formation of the expression pattern.
The biological function and the physiologic role of individual cancer/testis antigens is still obscure 2, 3 ; therefore, we are currently tracking prospective data for a correlation of the course of Tables 1 and 2 We read with interest the article by Choi et al 1 (November 2004) concerning the incidence and risk factors of delayed pneumothorax after transthoracic fine-needle aspiration (FNA) of pulmonary lesions guided by a variety of radiologic techniques. The article is both well written and informative. As the authors indicate in their discussion, it is a common practice to obtain a chest radiograph typically 4 h after percutaneous transthoracic needle aspiration. 2 The incidences of early and delayed pneumothorax in the study by Choi et al were 18.6% and 3.3%, respectively. However, all of the patients in their study who required tube thoracostomy for delayed pneumothorax were symptomatic. This represents Ͻ 1% of their study population. Interestingly, none of the patients in this study with delayed pneumothorax had undergone CT-guided FNA. We have previously reported that immediate pneumothorax develops in 17.2 to 24.1% of patients undergoing CT-guided FNA. 3, 4 In our studies, delayed pneumothorax occurs in 2.5 to 3.1% of patients who underwent this procedure. Moreover, delayed pneumothorax requiring intervention with pleural space evacuation occurred in 1.3 to 1.6% of patients.
While we agree the conclusion of Choi et al that late pneumothorax is clinically important, the practice of obtaining a delayed postprocedure chest radiograph after CT-guided FNA does not appear to be an efficient use of resources. Based on our research, chest radiography appears to add little information regarding lung expansion to that obtained by CT at the end of CT-guided FNA. Instruction to seek medical attention in the event of symptoms of pneumothorax appears be a more effective method of addressing this potential complication.
